Cardiff Oncology (CRDF) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Cardiff Oncology Revenue Highlights


Latest Revenue (Y)

$488.00K

Latest Revenue (Q)

$165.00K

Main Segment (Y)

Royalty

Main Geography (Y)

Royalty

Cardiff Oncology Revenue by Period


Cardiff Oncology Revenue by Year

DateRevenueChange
2023-12-31$488.00K26.42%
2022-12-31$386.00K7.52%
2021-12-31$359.00K-1.91%
2020-12-31$365.99K49.38%
2019-12-31$245.00K-35.19%
2018-12-31$378.00K-25.15%
2017-12-31$505.00K32.55%
2016-12-31$381.00K21.73%
2015-12-31$313.00K11.79%
2014-12-31$280.00K8.01%
2013-12-31$259.25K-42.39%
2012-12-31$450.00K74.62%
2011-12-31$257.70K-3.00%
2010-12-31$265.67K-59.13%
2009-12-31$650.00K100.00%
2006-01-31-100.00%
2005-01-31--

Cardiff Oncology generated $488.00K in revenue during NA 2023, up 26.42% compared to the previous quarter, and up 129.10% compared to the same period a year ago.

Cardiff Oncology Revenue by Quarter

DateRevenueChange
2024-09-30$165.00K1.23%
2024-06-30$163.00K-20.49%
2024-03-31$205.00K31.41%
2023-12-31$156.00K10.64%
2023-09-30$141.00K30.56%
2023-06-30$108.00K30.12%
2023-03-31$83.00K-35.16%
2022-12-31$128.00K37.63%
2022-09-30$93.00K2.20%
2022-06-30$91.00K22.97%
2022-03-31$74.00K-44.36%
2021-12-31$133.00K54.65%
2021-09-30$86.00K26.47%
2021-06-30$68.00K-5.56%
2021-03-31$72.00K-39.63%
2020-12-31$119.25K-12.57%
2020-09-30$136.40K219.94%
2020-06-30$42.63K-37.03%
2020-03-31$67.70K-27.20%
2019-12-31$93.00K79.93%
2019-09-30$51.69K-62.55%
2019-06-30$138.00K-14.81%
2019-03-31$162.00K107.69%
2018-12-31$78.00K-11.73%
2018-09-30$88.36K-20.97%
2018-06-30$111.81K11.66%
2018-03-31$100.14K-45.87%
2017-12-31$185.00K50.01%
2017-09-30$123.33K20.90%
2017-06-30$102.01K7.34%
2017-03-31$95.04K39.76%
2016-12-31$68.00K-23.69%
2016-09-30$89.11K-13.82%
2016-06-30$103.40K-14.18%
2016-03-31$120.49K52.19%
2015-12-31$79.17K38.10%
2015-09-30$57.33K16.17%
2015-06-30$49.35K-61.14%
2015-03-31$126.97K125.13%
2014-12-31$56.40K-1.40%
2014-09-30$57.20K2.82%
2014-06-30$55.63K-49.86%
2014-03-31$110.95K134.24%
2013-12-31$47.37K8.25%
2013-09-30$43.76K-10.70%
2013-06-30$49.00K-58.87%
2013-03-31$119.12K-27.03%
2012-12-31$163.25K-22.81%
2012-09-30$211.50K409.64%
2012-06-30$41.50K21.51%
2012-03-31$34.15K1.19%
2011-12-31$33.75K-38.64%
2011-09-30$55.00K-31.13%
2011-06-30$79.86K-10.35%
2011-03-31$89.08K-57.58%
2010-12-31$210.00K600.00%
2010-09-30$30.00K50.00%
2010-06-30$20.00K100.00%
2010-03-31--

Cardiff Oncology generated $165.00K in revenue during Q3 2024, up 1.23% compared to the previous quarter, and up 152.78% compared to the same period a year ago.

Cardiff Oncology Revenue Breakdown


Cardiff Oncology Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 20Dec 19
Royalty$365.99K$243.14K
Service-$1.50K

Cardiff Oncology's latest annual revenue breakdown by segment (product or service), as of Dec 20: Royalty (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 19Sep 19Jun 19
Royalty$92.58K$51.69K$36.85K
Service--$101.43K

Cardiff Oncology's latest quarterly revenue breakdown by segment (product or service), as of Dec 19: Royalty (100.00%).

Cardiff Oncology Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 20Dec 19
Royalty$365.99K$243.14K
Service-$1.50K

Cardiff Oncology's latest annual revenue breakdown by geography, as of Dec 20: Royalty (100.00%).

Quarterly Revenue by Country

CountryDec 19Sep 19Jun 19
Royalty$92.58K$51.69K$36.85K
Service--$101.43K

Cardiff Oncology's latest quarterly revenue breakdown by geography, as of Dec 19: Royalty (100.00%).

Cardiff Oncology Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
MREOMereo BioPharma Group$10.00M-
BOLTBolt Biotherapeutics$7.88M$1.14M
CUECue Biopharma$5.49M$3.34M
AUTLAutolus Therapeutics$1.70M-
LYRALyra Therapeutics$1.56M$195.00K
CRDFCardiff Oncology$488.00K$165.00K
EYENEyenovia$3.79K$1.63K
NLSPNLS Pharmaceutics--
CGEMCullinan Oncology--
RVPHReviva Pharmaceuticals--
PDSBPDS Bio--
DAWNDay One Biopharmaceuticals-$20.07M
INABIN8bio--
CGTXCognition Therapeutics--
KODKodiak Sciences--
LTRNLantern Pharma--
SLSSELLAS Life Sciences Group--
RNAZTransCode Therapeutics--

CRDF Revenue FAQ


What is Cardiff Oncology’s yearly revenue?

Cardiff Oncology's yearly revenue for 2023 was $488K, representing an increase of 26.42% compared to 2022. The company's yearly revenue for 2022 was $386K, representing an increase of 7.52% compared to 2021. CRDF's yearly revenue for 2021 was $359K, representing a decrease of -1.91% compared to 2020.

What is Cardiff Oncology’s quarterly revenue?

Cardiff Oncology's quarterly revenue for Q3 2024 was $165K, a 1.23% increase from the previous quarter (Q2 2024), and a 17.02% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $163K, a -20.49% decrease from the previous quarter (Q1 2024), and a 50.93% increase year-over-year (Q2 2023). CRDF's quarterly revenue for Q1 2024 was $205K, a 31.41% increase from the previous quarter (Q4 2023), and a 146.99% increase year-over-year (Q1 2023).

What is Cardiff Oncology’s revenue growth rate?

Cardiff Oncology's revenue growth rate for the last 3 years (2021-2023) was 35.93%, and for the last 5 years (2019-2023) was 99.18%.

What are Cardiff Oncology’s revenue streams?

Cardiff Oncology's revenue streams in c 20 are Royalty

What is Cardiff Oncology’s main source of revenue?

For the fiscal year ending Dec 20, the largest source of revenue of Cardiff Oncology was Royalty. This segment made a revenue of $365.99K, representing 100.00% of the company's total revenue.